Key terms

About FULC

Fulcrum Therapeutics, Inc. is a clinical stage biopharmaceutical company. The firm develops new medicines and focuses on unlocking gene control mechanisms to develop small molecule therapies. Its product candidate includes Losmapimod and FTX-HbF. The company was founded by Michael R. Green, Danny Reinberg, Rudolf Jaenisch, Jeannie T. Lee, and Bradley E. Bernstein on August 18, 2015 and is headquartered in Cambridge, MA.

Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
     
52-week range
     
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date

Key terms

Smart score

Latest FULC news

Mar 19 1:50am ET Analysts Offer Insights on Healthcare Companies: Arcutis Biotherapeutics (ARQT), Fulcrum Therapeutics (FULC) and AC Immune SA (ACIU) by TipRanks Mar 18 7:02am ET Fulcrum Therapeutics appoints Horn as Chief Medical Officer by TipRanks Mar 13 8:08am ET RBC Capital starts Fulcrum Therapeutics at Outperform, sees two pipeline shots by TipRanks Mar 13 7:28am ET Fulcrum Therapeutics initiated with an Outperform at RBC Capital by TipRanks Mar 08 10:46am ET Biotech Alert: Searches spiking for these stocks today by TipRanks Mar 05 6:14pm ET Fulcrum Therapeutics CEO buys $492K in common stock by TipRanks Mar 01 1:04am ET Strong Buy Rating for Fulcrum Therapeutics Amidst Promising Clinical Progress and Financial Stability by TipRanks Feb 28 7:47am ET Oppenheimer Sticks to Their Buy Rating for Fulcrum Therapeutics (FULC) by TipRanks Feb 28 7:32am ET Analysts Offer Insights on Healthcare Companies: Fulcrum Therapeutics (FULC), Ligand Pharma (LGND) and Alphatec Holdings (ATEC) by TipRanks Feb 28 7:28am ET Fulcrum Therapeutics price target raised to $15 from $13 at Piper Sandler by TipRanks Feb 28 6:17am ET Fulcrum Therapeutics price target raised to $17 from $14 at H.C. Wainwright by TipRanks Feb 27 5:14pm ET Fulcrum Therapeutics files $350M mixed securities shelf by TipRanks Feb 27 7:08am ET Fulcrum Therapeutics expects cash to fund operations into 2026 by TipRanks Feb 27 7:08am ET Fulcrum Therapeutics reports Q4 EPS (40c), consensus (43c) by TipRanks Feb 09 8:29am ET Stifel Nicolaus Sticks to Their Buy Rating for Fulcrum Therapeutics (FULC) by TipRanks

No recent news articles are available for FULC

No recent press releases are available for FULC

FULC Financials

1-year income & revenue

Key terms

FULC Forecasts

analyst rating

  • buy
  • hold
  • sell

We're sorry, but this
information is
temporarily unavailable.

1-year stock price forecast

FULC Competitors

$ Market cap P/E ratio $ Price 1d change 52-week range

Key terms

Latest investing news

Donald Trump might no longer own a majority of TMTG after a new public share offering.
Joe Raedle/Getty Images
Trump stock tanks after announcing massive share sale
1040 US Individual Income Tax Return Form
Nora Carol Photography/Moment RF/Getty Images
Three ways investors can minimize their tax payments
People walk past the New York Stock Exchange (NYSE) on April 10, 2024 in New York City.
Spencer Platt/Getty Images
Dow closes nearly 500 points lower on fears of potential Iranian attack on Israel
JPMorgan beat earnings expectations this Friday, unofficially kicking off the first quarter earnings season.
Win McNamee/Getty Images
Jamie Dimon says chance of a bad economy is ‘higher than other people think’